宏源药业 reported revenue of ¥1.34B for the period ended 2026-06-30, +52.1% year on year. Net income was ¥0.16B, a 11.6% net margin on a 23.1% gross margin. The largest revenue line is 锂电池材料 at 45% of the total. Free cash flow for the period was ¥-0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.34B | +52.1% |
| Gross profit | ¥0.31B | — |
| Operating income | ¥0.22B | — |
| Net income | ¥0.16B | — |
| Gross margin | 23.1% | Net margin 11.6% |
| Revenue Q/Q | -9.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 锂电池材料 | ¥0.61B | 45.4% |
| 原料药及医药中间体 | ¥0.50B | 36.9% |
| 其他主营业务 | ¥0.18B | 13.0% |
| 其他(补充) | ¥0.06B | 4.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.03B | 76.9% |
| R&D | ¥0.05B | 3.9% |
| SG&A | ¥0.06B | 4.2% |
| Tax & other | ¥0.07B | 4.9% |
| Item | Amount |
|---|---|
| Total assets | ¥6.41B |
| Total liabilities | ¥1.81B |
| Shareholders' equity | ¥4.60B |
| Equity / assets | 71.8% |
| Operating cash flow | ¥0.05B |
| Capital expenditure | ¥0.09B |
| Free cash flow | ¥-0.04B |
| Cash conversion (OCF / net income) | 25% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
杰创智能 ・ 威尔高 ・ 同星科技 ・ 通力科技 ・ 华融化学 ・ 普蕊斯 ・ 富士莱 ・ 艾布鲁 ・ 格力博 ・ 恒工精密 ・ 海看股份 ・ 泰恩康
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies